Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2006 > Volume 15 Number 1 January 2006 > DEVICE EVALUATION > North American Multicenter Experience with the On-X Prosthetic Heart Valve

North American Multicenter Experience with the On-X Prosthetic Heart Valve

Kathleen W. McNicholas, Tom D. Ivey, Jacques Metras, Szabolcs Szentpetery, Steven W. Marra, Roy G. Masters, Emery W. Dilling, Mark S. Slaughter, Michael J. Mack

Christiana Care Health System, Newark, DE, USA, Ohio Heart Institute, Cincinnati, OH, USA, Hôpital Laval, Quebec City, Canada, Sentara Norfolk General Hospital, Norfolk, VA, USA, Cooper Hospital, Camden, NJ, USA, Ottawa Heart Center, Ottawa, Ontario, Canada, St. David’s Hospital, Austin, TX, USA, Christ Hospital, Oak Lawn, IL, USA, Medical City, Dallas, TX, USA

Background and aim of the study: This ongoing, longitudinal, multi-center, North American study was designed to evaluate the safety and effectiveness of the On-X® valve.
Methods: The On-X valve was implanted in isolated aortic (AVR) and mitral (MVR) valve replacement patients at nine North American centers. Follow up was 98.6% complete. Anticoagulation compliance was evaluated by collection of international normalized ratio (INR) results in all patients throughout their postoperative follow up. Adverse events were recorded according to the AATS/STS guidance criteria. Hematologic studies were conducted postoperatively to evaluate hemodynamics and hemolysis.
Results: In total, 142 AVR and 142 MVR implants were performed; the mean follow up was 4.5 years; total follow up was 1,273 patient-years (pt-yr). At implant, the mean patient age was 59.2 years (range: 28 to 85 years); 71.8% of patients who underwent AVR and 33.1% who underwent MVR were males.
Preoperatively, 89.4% of AVR patients and 56.3% of

MVR patients were in sinus rhythm. The cardiac disease etiology was primarily stenotic, calcific degeneration in AVR and rheumatic or degenerative regurgitation in MVR. Hemolysis represented by postoperative elevation of serum lactate dehydrogenase was very low (median 217 IU after AVR and 251 IU after MVR at one year (82% AVR and 98% MVR of upper normal). Late adverse event rates were low, most notably thromboembolism (0.9%/pt-yr after AVR; 1.6%/pt-yr after MVR) and thrombosis. Kaplan-Meier event-free rates at five years were correspondingly high. Anticoagulation compliance analysis showed only about 40% of INR readings to be within target ranges postoperatively; thus, the control range achieved was much greater than the desired target, as might generally be expected for clinic-controlled INR.
Conclusion: The On-X valve performed well in this study, confirming the original design intent of minimal hemolysis and low adverse event rates.
The Journal of Heart Valve Disease 2006;15:73-79

North American Multicenter Experience with the On-X Prosthetic Heart Valve

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.